Market Snapshot
S&P Futures
3,779.5
Dow Futures
30,569
Nasdaq Futures
11,622.75
Altimmune, Inc. (ALT) stock rallied over 8.35% intraday to trade at $12.20 a share on NASDAQ. The stock opened with a gain of 4.45% at $11.22 and touched an intraday high of $12.37, rising 8.35% against the last close of $11.26. The stock went to a low of $10.9 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-07-05 | $11.22 | $12.37 | $10.9 | $12.2 | 1,755,267 |
2022-07-01 | $11.68 | $12.01 | $10.79 | $11.26 | 1,581,200 |
2022-06-30 | $11.52 | $11.95 | $11.2 | $11.7 | 1,102,700 |
2022-06-29 | $11.46 | $12.005 | $10.901 | $11.77 | 2,171,300 |
2022-06-28 | $11.54 | $11.73 | $10.81 | $11.64 | 2,086,500 |
2022-06-27 | $10.18 | $12.028 | $9.745 | $11.75 | 4,019,200 |
2022-06-24 | $10.67 | $11 | $9.6 | $10.29 | 7,091,800 |
2022-06-23 | $9.37 | $10.65 | $9.23 | $10.6 | 1,986,800 |
2022-06-22 | $9.08 | $9.601 | $9.001 | $9.44 | 1,271,500 |
2022-06-21 | $8.97 | $9.77 | $8.7 | $9.32 | 2,551,900 |
Employees-
Beta0.48
Sales or Revenue4.41 Million
5Y Sales Change6.40%
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Altimmune, Inc. (NASDAQ: ALT) stock price is $12.2 as of the last check on Tuesday, July 5. During the trading session, ALT stock reached the peak price of $12.37 while $10.9 was the lowest point it dropped to.
The NASDAQ listed ALT is part of Biotechnology industry that operates in the broader Health Care sector. Altimmune, Inc. , a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
Mr. Richard I. Eisenstadt M.B.A.
CFO and Principal Financial & Accounting Officer
Dr. Vipin K. Garg Ph.D.
Pres, CEO & Director
Mr. Richard I. Eisenstadt M.B.A.
Chief Financial Officer
Dr. M. Scot Roberts Ph.D.
Chief Scientific Officer
ALT stock traded closed the last session at $12.2, which is $0.94 or 8.35% lower than its previous close of $11.26. ALT's current trading price is 218.54% lower than its 52-week high of $17.26 where as its distance from 52-week low of 3.83% is -29.32%.
Number of ALT employees currently stands at -. ALT operates from 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878, United States.
Official Webiste of $ALT is: https://altimmune.com
ALT could be contacted at ALT operates from 910 Clopper Road, Suite 201S, Gaithersburg, MD 20878, United States, or at phone #240 654 1450 and can also be accessed through its website.
ALT stock volume for the day was 1,754,027 shares while in the previous session number of ALT shares traded was 1,755,267 . The average number of ALT shares traded daily for last 3 months was 1.3 Million.
The percentage change in ALT stock occurred in the recent session was 8.35% while the dollar amount for the price change in ALT stock was $0.94.
In the recent session, the day high for ALT stock was $12.37 while the low for ALT stock touched on the day was $10.9.
The market value of ALT currently stands at 547.9 Million with its latest stock price at $12.2 and 43.97 Million of its shares outstanding.